A product of independent beta probabilities dose escalation design for dual‐agent phase I trials
Open Access
- 29 January 2015
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 34 (8) , 1261-1276
Abstract
Dual‐agent trials are now increasingly common in oncology research, and many proposed dose‐escalation designs are available in the statistical literature. Despite this, the translation from statistical design to practical application is slow, as has been highlighted in single‐agent phase I trials, where a 3 + 3 rule‐based design is often still used. To expedite this process, new dose‐escalation designs need to be not only scientifically beneficial but also easy to understand and implement by clinicians. In this paper, we propose a curve‐free (nonparametric) design for a dual‐agent trial in which the model parameters are the probabilities of toxicity at each of the dose combinations. We show that it is relatively trivial for a clinician's prior beliefs or historical information to be incorporated in the model and updating is fast and computationally simple through the use of conjugate Bayesian inference. Monotonicity is ensured by considering only a set of monotonic contours for the distribution of the maximum tolerated contour, which defines the dose‐escalation decision process. Varied experimentation around the contour is achievable, and multiple dose combinations can be recommended to take forward to phase II. Code for R, Stata and Excel are available for implementation. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.Keywords
Funding Information
- Medical Research Council (U1052.00.014)
This publication has 22 references indexed in Scilit:
- A Generalized Continual Reassessment Method for Two-Agent Phase I TrialsStatistics in Biopharmaceutical Research, 2013
- Adaptive designs for dual-agent phase I dose-escalation studiesNature Reviews Clinical Oncology, 2013
- General Classes of Multiple Binary Regression Models in Dose Finding Problems for Combination TherapiesJournal of the Royal Statistical Society Series C: Applied Statistics, 2012
- Continual Reassessment Method for Partial OrderingBiometrics, 2011
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic AgentsBiometrics, 2009
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two AgentsBiometrics, 2009
- Bayesian Dose Finding in Oncology For Drug Combinations by Copula RegressionJournal of the Royal Statistical Society Series C: Applied Statistics, 2009
- Critical aspects of the Bayesian approach to phase I cancer trialsStatistics in Medicine, 2008
- Two‐Dimensional Dose Finding in Discrete Dose SpaceBiometrics, 2005
- Dose‐Finding with Two Agents in Phase I Oncology TrialsBiometrics, 2003